Richard Kaplan

机构：Desmond Tutu HIV Foundation · ORCID：0000-0003-1565-4704

发表论文 77 篇 · 总被引 3388 次 · h-index 30

代表论文

• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials (2018 · The Lancet · 被引 385)
• Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial (2019 · The Lancet Infectious Diseases · 被引 198)
• Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial (2018 · Clinical Infectious Diseases · 被引 173)
• Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial (2019 · Clinical Infectious Diseases · 被引 112)
• HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town (2019 · PLoS ONE · 被引 42)
• HIV and TB co-infection in the ART era: CD4 count distributions and TB case fatality in Cape Town (2018 · BMC Infectious Diseases · 被引 35)